Luxembourg’s HIV Decline Signals Progress but Highlights Persistent Vulnerabilities

Luxembourg has recorded one of its most encouraging drops in HIV diagnoses in more than a decade, a shift health officials credit to wider testing, sustained treatment coverage and better-targeted prevention efforts. The Grand Duchy confirmed 43 new HIV diagnoses in 2024, down from 53 the year before and sharply lower than the post-pandemic spike of 100 cases recorded in 2021. While the numbers are small by international standards, the trend marks a significant turn for a country that, like most of Europe, faced steady or rising infections through the 2010s.

The arc of Luxembourg’s epidemic mirrors the trajectory seen across much of the continent. HIV first appeared in the country in the early 1980s, with the earliest cases linked to the same routes of transmission recognised globally at the time – sexual transmission among gay and bisexual men, and infections linked to injecting drug use. As in neighbouring states, the epidemic grew through the late 1980s and into the 1990s, peaking before the widespread availability of antiretroviral therapy began to suppress deaths and reduce transmission. The early 2000s brought stable or slowly declining numbers, but new diagnoses began rising again in the mid-2010s as awareness dipped and transmission patterns diversified.

The most dramatic peak in recent memory came in 2021, when Luxembourg confirmed 100 new diagnoses, a surge partly shaped by the rebound in testing and social activity following the Covid-19 lockdowns. Since then, the curve has bent downwards. Officials attribute the change to a combination of persistent testing – more than 90,000 tests were recorded in 2024 alone, in a country of barely 660,000 people and high treatment uptake. A large majority of those diagnosed are now promptly placed on antiretroviral therapy, and most achieve an undetectable viral load, effectively halting further transmission.

Public-health workers say Luxembourg’s size has worked to its advantage. The country’s concentrated health infrastructure allows for rapid linkage to care, and community organisations have broadened their outreach, offering free condom distribution at events, promoting pre-exposure prophylaxis (PrEP), and encouraging regular screening among groups most at risk. Anonymous testing and low-threshold services have also been expanded, targeting harder-to-reach populations.

Yet Luxembourg’s progress is set against a more uneven European backdrop. Across the EU and wider WHO European Region, roughly 24,000 and 106,000 new diagnoses respectively were recorded in 2024 – numbers that show the continent remains far from its target to end HIV as a public-health threat by 2030. Late diagnosis continues to undermine efforts – in many countries nearly half of those who test positive learn their status only after the virus has begun to damage their immune systems, making treatment less effective and increasing the chance of earlier transmission. Luxembourg’s rate of late diagnoses is lower than the EU average but still represents a sizeable share of cases.

Neighbouring France, long seen as a leader in prevention, has struggled to maintain downward momentum. While diagnoses among French-born men who have sex with men have fallen sharply thanks to widespread testing and PrEP adoption, overall numbers have stagnated due to persistently high rates of late diagnosis and rising infections among people born abroad. The Netherlands, which enjoyed one of Europe’s steepest declines earlier in the decade, has also stalled, with recent years showing little movement as clinics reach those easiest to contact while struggling to identify remaining pockets of transmission.

Outside Europe, some of the world’s fastest progress has been recorded in sub-Saharan Africa, where aggressive, community-led programmes have driven infections down dramatically since 2010. These gains, backed by strong political commitment and external funding, have shifted the centre of the global epidemic – for the first time, most new infections are now occurring outside the region, highlighting both the success of African countries and the worrying stagnation elsewhere.

Luxembourg’s recent trajectory suggests that the fundamentals of HIV control – easy access to testing, swift treatment, and broad prevention – remain as powerful as ever. But the shift in transmission patterns, with heterosexual transmission rising in relative share and a rare mother-to-child case recently detected, shows how quickly gaps can re-emerge. Campaigners warn that continued investment is essential, particularly in reaching migrant communities, reducing stigma, and ensuring PrEP services become as routine as other elements of sexual healthcare.

The fall in diagnoses has given Luxembourg reason for cautious optimism. But as with the rest of Europe, the gains are fragile, and the history of the epidemic from its peak decades ago to its present downturn – is a reminder that progress depends not only on medical advances but on the political will to keep prevention and care within everyone’s reach.